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Background Coronavirus disease 2019 (COVID-19) myocarditis is emerging as a component of the hyperactive inflammatory response
secondary to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Isolated gastrointestinal symptoms are un-
common presenting features in adults with COVID-19 myocarditis. The availability of antibody testing is a valuable add-
ition to the confirmation of COVID-19, when repeated reverse transcriptase–polymerase chain reaction of nasopharyn-
geal swabs are negative.
...............................................................................................................................................................................................................
Case summary A young healthcare worker presented with dizziness and pre-syncope, 4 weeks after his original symptoms that included
fever, lethargy, and diarrhoea. Despite 2 weeks of isolation, followed by a quiescent spell, his symptoms had returned.
Shortly after, he presented in cardiogenic shock (left ventricular ejection fraction 25%), that required vasopressor support,
at the height of the COVID-19 pandemic. Cardiac magnetic resonance imaging suggested florid myocarditis. Three naso-
pharyngeal swabs (Days 1, 3, and 5) were negative for SARS-CoV-2, but subsequent serology (Day 13) confirmed the
presence of SARS-CoV-2 IgG. Treatment with intravenous immunoglobulin and glucocorticoids led to full recovery.
...............................................................................................................................................................................................................
Discussion Our case study highlights the significance of the use of the available serological assays for diagnosis of patients presenting
late with SARS-CoV-2. Importantly, it supports further research in the use of immunomodulatory drugs for the hyperin-
flammatory microenvironment induced by COVID-19.
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Learning points
• To appreciate the utility of serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG in those for whom
viral nasopharyngeal nucleic acid testing is negative.
• To highlight that the inflammatory effects of SARS-CoV-2 infection can occur late after initial viral symptoms have abated and may need
immunosuppression.
• To be aware of the role of cardiac magnetic resonance in coronavirus disease 2019 myocarditis.
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Coronavirus disease 2019 (COVID-19) is an infectious disease
caused by severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2). There are over 73 million confirmed cases across the globe,
with evidence of a hyperactive immune response that frequently (7–
20%) affects the myocardium and promotes cardiovascular injury.1–3
We report the case of a healthcare worker, with presenting features
similar to that of paediatric inflammatory multisystem syndrome tem-
porally associated with SARS-CoV-2 (PIM-TS), with the diagnosis
only being confirmed through antibody testing.
Timeline
Case presentation
In early May 2020, a 37-year-old Caucasian healthcare worker, with
no past medical history, presented to the emergency department
with dizziness and pre-syncope. One month prior to admission, he
described fever associated with lethargy and diarrhoea. His symp-
toms lasted 5 days with steady improvement. Swabs were not rou-
tinely available to healthcare professionals, and he began self-isolation
on the suspicion that this illness was caused by COVID-19, particular-
ly given his occupational exposure risk. He initially recovered but 2
weeks later he had a recurrence of symptoms with further fever,
diarrhoea, and new-onset of dizziness. On arrival to hospital, he was
clinically shocked (blood pressure 75/50, heart rate 120 beats per mi-
nute), febrile (39C), and tachypnoeic (>30 breaths per minute), with
an oxygen saturation level of 97% on 3 L per minute of supplemental
oxygen. Physical examination revealed a raised jugular venous pres-
sure and coarse crepitations on auscultation. A bedside echocardio-
gram revealed global moderate-to-severe left ventricular (LV)
systolic dysfunction [ejection fraction (EF) 35–40%].
He was transferred to critical care and was commenced on milri-
none and noradrenaline. Within 24 h, given worsening of myocardial
function (EF 25%) and strong suspicion of viral myocarditis, a single
dose of 2 g/kg of intravenous immunoglobulin was administered, and
hydrocortisone (50 mg QDS) started. He was anticoagulated with a
heparin infusion, and high-dose Vitamin B & C (PabrinexVR ) was
initiated.
Laboratory investigations revealed leucocytosis (36 109/L), lym-
phopenia (0.6 109/L), elevated troponin (490 ng/l), brain natriuretic
peptide (>35 000 ng/l), ferritin (8681 mg/L), and a D-dimer of
2782 ng/mL. He had an acute kidney injury (creatinine of 130 mmol/
L), was coagulopathic (international normalized ratio of 1.5), and had
a transaminitis (alanine transaminase of 538 U/L). His procalcitonin
was 14.78 mg/L. Blood, urine, and stool cultures revealed no bacterial
growth. He had a total of three nasopharyngeal swabs (Day 1, Day 3,
28 days before admission Initial symptoms: fever, diarrhoea, and lethargy. Symptoms subsided after 5 days.
5 days before admission Recurrence of symptoms: fever and diarrhoea.
Admission (2 May 2020) Re-presented to the emergency department with fever, diarrhoea, and new-onset dizziness. Given his occupation, there
was increased suspicion of coronavirus disease 2019 (COVID-19). Transferred to critical care for haemodynamic
support. Milrinone and noradrenaline were commenced. He did not require any other organ support.
Echocardiogram revealed global left ventricular impairment (estimated at 35%), with biochemical evidence of myocar-
dial injury [brain natriuretic peptide (BNP) > 35 000 ng/L; troponin 490 ng/L].
Days 1–4 Two nasopharyngeal swabs (Days 1 and 3) were negative for severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2). Within 24 h of admission, there was worsening of myocardial function and was commenced on intravenous
immunoglobulin (2 g/kg), and hydrocortisone (50 mg QDS). Chest computed tomography showed evidence of pneu-
monia, not characteristic of COVID-19 pneumonia, and therefore broad-spectrum antibiotics were started.
Day 5 Transferred to another institution, with another nasopharyngeal swab (Day 5) returning negative.
Day 7 Commenced on a weaning regime (weekly reduction) of Prednisolone (0.75 mg/kg/day).
Day 10 Inotropes were stopped. Cardiac magnetic resonance (CMR) showed improvement in myocardial function, whilst con-
firming myocarditis.
Day 12 Given haemodynamic stability, beta-blocker, angiotensin-converting enzyme (ACE) inhibitor, and a mineralocorticoid
receptor antagonist (MRA) were commenced.
Day 13 Once available, SARS-CoV-2 IgG was positive.
Day 14 Discharged from hospital, with 40 mg of Prednisolone.
Day 19 (20 May 2020) Troponin and BNP had normalized, with teleconsulting revealing absence of dizziness, and improved exercise
tolerance.
Day 29 Repeat CMR demonstrated significant improvement in the extent of patchy late gadolinium enhancement, with normal
biventricular size and systolic function.
Day 208 (24 November 2020) He remains on a slowly weaning (reduced by 1 mg every 3 weeks), low dose (4 mg) of Prednisolone as well as a beta-
blocker, ACE inhibitor, and MRA.




























































and Day 5 of admission) which were all negative for SARS-CoV-2.
No other viral pathology, including influenza and HIV, was detected
and the serum autoimmune panel was normal. The electrocardio-
gram revealed sinus tachycardia. Computed tomography of the chest
revealed extensive bilateral lower lobe consolidation, with small
pleural effusions, not typical of COVID-19 pneumonia (Figure 1). On
account of his imaging and a clinical suspicion of a superimposed bac-
terial pneumonia, he was commenced on linezolid, clarithromycin,
and piperacillin-tazobactam.
Serial echocardiograms demonstrated worsening biventricular
function, with a reduction in global LV ejection fraction (LVEF) from
35% to 21% (Day 3 of admission) and worsening of right ventricular
(RV) function and morphology (Video 1). The subsequent echocar-
diograms (Day 3) revealed LV wall thickening, bi-atrial dilatation, and
increased pulmonary artery systolic pressures. There was an initial
improvement in myocardial function (Day 5) with an LVEF of 29%.
On Day 7, prednisolone (0.75 mg/kg/day) was substituted for hydro-
cortisone, which coincided with a rapid recovery in myocardial func-
tion. By Day 11, there was biochemical (troponin—108 ng/L) and
radiological improvement in cardiac function. Cardiac magnetic res-
onance (CMR) imaging showed evidence of myocarditis with LV wall
thickening, inhomogeneity of T1/T2 mapping values, and patchy non-
infarct pattern late gadolinium enhancement (LGE) in the inferolat-
eral and apical septal walls (Figure 2, Video 2). This also demonstrated
a recovery of overall LV systolic function (LVEF 70%), with normal-
ization of RV volumes and function.
Following full recovery of cardiac function and cessation of all
organ support, the serum antibody test result became available,
which confirmed the presence of SARS-CoV-2 IgG. He was
started on an angiotensin-converting enzyme inhibitor, a beta-
blocker, and a mineralocorticoid receptor antagonist. The patient
remained asymptomatic on discharge and remains on a slowly
weaning regimen of prednisolone. Whilst his repeat CMR demon-
strated resolution of ventricular function, small areas of patchy
LGE persisted, illustrating the potential longer-term effects of
COVID-19.4
Discussion
Presentations of COVID-19 infection are diverse, with a broad range
of clinical severity. Extrapulmonary manifestations have been fre-
quently described, and commonly involve cardiovascular complica-
tions.5 Myocardial injury, defined by an increase in troponin, is
thought to affect 20–30% of patients and is strongly associated with
mortality.5 Notably, COVID-19 related myocarditis, has been sug-
gested to be the outcome of either direct cardiomyocyte viral infiltra-
tion or a response to the hosts ‘cytokine storm’. This feature of the
late, hyperinflammatory phase of the disease is associated with critical
illness and is seemingly more prevalent in children and young
adults.5,6
The significant neutrophilia and procalcitonin raised the possibil-
ity of a bacterial cause with consequent septic cardiomyopathy.
However, his occupational exposure, biphasic illness, significant
lymphopenia and negative microbiological screen suggested viral
myocarditis. CMR was particularly useful in the confirmation of
the diagnosis. COVID-19 is associated with multiple mechanisms
of myocardial injury which can be a challenge to delineate on clin-
ical grounds. CMR was able to demonstrate the typical patchy
LGE associated with myocarditis and also demonstrated that there
was no myocardial infarction and no characteristic Takotsubo
features.
There were several features that were consistent with PIM-TS,
where acute heart failure is attributed to myocardial oedema or stun-
ning.6 Notably, gastrointestinal symptoms are prominent presenting
traits, with the majority being diagnosed serologically.3 Negative
nasopharyngeal antigen testing with positive serum antibody is typical
of PIM-TS and may reflect the aberrant development of acquired im-
munity to SARS-CoV-2.7 Importantly, multiple negative viral antigen
Figure 1 Computed tomography chest illustrating bilateral basal consolidation.
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tests does not exclude the diagnosis.7 Current data suggest that re-
verse transcriptase–polymerase chain reaction positivity declines by
Week 3 and becomes undetectable thereafter. Serological testing is
therefore an important emerging tool in the diagnosis of those who
present late. His occupation was a factor in ongoing clinical suspicion
and testing.7
With the presence of a hyperinflammatory microenvironment,
the use of immunomodulators may appear justified. However,
preceding evidence has suggested otherwise. The use of cortico-
steroids, in patients with Middle East respiratory syndrome-CoV
and SARS-CoV, has been associated with worse outcomes, includ-
ing prolonged hospitalisation, higher need for ventilation, renal re-
placement therapy and need for intensive care. This may be due
to inhibition of appropriate immune responses and delay in patho-
gen clearance.8,9
In the absence of validated treatment strategies and with
a case-fatality rate of 49% in critically unwell patients, the
inflammatory mediators of COVID-19 have become plausible
targets in achieving faster recovery or lowering risk of
death.10 Most recently, the use of dexamethasone has shown
to reduce mortality, by one fifth, in patients receiving oxy-
gen alone.11
Figure 2 Matching T2 and late gadolinium enhancement images confirming myocarditis.
Video 1 Echocardiogram demonstrating low biventricular systol-
ic function.














































































COVID-19 myocarditis should be considered in those with a history
of a viral prodrome, symptoms of cardiac dysfunction and elevated
troponin. Occupation remains a significant potential risk factor. With
a protracted but suspicious illness and a negative microbiology and
autoantibody screen, SARS-CoV-2 antibody testing may support a
diagnosis of late inflammatory COVID-19 in the presence of multiple
negative antigen swab tests. CMR was crucial in the delineation of
COVID myocarditis given the ability to exclude infarction and dem-
onstrate myocardial oedema. In patients with a hyper-inflammatory
response and myocarditis, immunosuppressive therapy should be
considered.
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Video 2 Cardiac magnetic resonance illustrating myocardial
oedema.
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